TY  - JOUR
AU  - Goldschmidt, Hartmut
AU  - Mai, Elias K
AU  - Dürig, Jan
AU  - Scheid, Christof
AU  - Weisel, Katja C
AU  - Kunz, Christina
AU  - Bertsch, Uta
AU  - Hielscher, Thomas
AU  - Merz, Maximilian
AU  - Munder, Markus
AU  - Lindemann, Hans-Walter
AU  - Hügle-Dörr, Barbara
AU  - Tichy, Diana
AU  - Giesen, Nicola
AU  - Hose, Dirk
AU  - Seckinger, Anja
AU  - Huhn, Stefanie
AU  - Luntz, Steffen
AU  - Jauch, Anna
AU  - Elmaagacli, Ahmet
AU  - Rabold, Bernhard
AU  - Fuhrmann, Stephan
AU  - Brossart, Peter
AU  - Goerner, Martin
AU  - Bernhard, Helga
AU  - Hoffmann, Martin
AU  - Hillengass, Jens
AU  - Raab, Marc S
AU  - Blau, Igor W
AU  - Hänel, Mathias
AU  - Salwender, Hans J
TI  - Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
JO  - Leukemia
VL  - 34
IS  - 7
SN  - 1476-5551
CY  - London
PB  - Springer Nature
M1  - DKFZ-2020-00358
SP  - 1853-1865
PY  - 2020
N1  - 2020 Jul;34(7):1853-1865
AB  - The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5
LB  - PUB:(DE-HGF)16
C6  - pmid:32034285
DO  - DOI:10.1038/s41375-020-0724-1
UR  - https://inrepo02.dkfz.de/record/153635
ER  -